← All trials
NCT05970679
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2022
- Primary completion
- Apr 13, 2023
- Completion date
- Apr 13, 2023
- First posted
- Aug 1, 2023
- Last posted
- Aug 1, 2023
- Enrollment
- 252
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daewon Pharmaceutical Co., Ltd.Lead sponsor
- Seoul National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.